Seasonal influenza vaccination and antiviral use in EU/EEA Member States
Overview of vaccine recommendations for 2017–2018 and vaccination coverage rates for 2015–2016 and 2016–2017 influenza seasons.
Seasonal influenza vaccination in Europe – Vaccination recommendations and coverage rates for 2013-14 and 2014-15
Overview of vaccination recommendations and coverage rates in the EU Member States for the 2013–14 and 2014–15 influenza seasons.
Questions and answers about antivirals
Frequently asked questions about the use of antivirals for prevention and treatment of influenza; What are the uses of antivirals against seasonal influenza? Which are the antivirals we use in Europe against seasonal influenza and who should get them? If antivirals are so good why don’t doctors give them out more often? Do people who have been immunized against influenza need antivirals?
Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europe
Pozo, F., Lina, B., Andrade, H.R., Enouf, V., Kossyvakis, A., Broberg, E., Daniels, R., Lackenby, A., Meijer, A.
Factsheet about seasonal influenza
Influenza is a contagious respiratory illness caused by influenza viruses that infect the nose, throat, and sometimes the lungs. It can cause mild to severe illness, and at times can lead to death. The best way to prevent flu is by getting a flu vaccine each year.
Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza - review of recent systematic reviews and meta-analyses
This ECDC expert opinion confirms earlier assessments by ECDC and national authorities that there is no significant new evidence to support any changes to the approved indications and recommended use of neuraminidase inhibitors (NAIs) in EU/EEA Member States.
Infographic: How do antivirals treat and protect against influenza?
This ECDC infographic explains how antivirals treat and protect against influenza. The recommendations to treat patients with severe influenza are based on the evidence from randomised controlled trials, observational studies, extrapolation from studies, and a generally benign safety profile of these medicines.